MX346252B - Procedimiento para producir antagonistas de los receptores del peptido relacionado con el gen de calcitonina. - Google Patents
Procedimiento para producir antagonistas de los receptores del peptido relacionado con el gen de calcitonina.Info
- Publication number
- MX346252B MX346252B MX2014011000A MX2014011000A MX346252B MX 346252 B MX346252 B MX 346252B MX 2014011000 A MX2014011000 A MX 2014011000A MX 2014011000 A MX2014011000 A MX 2014011000A MX 346252 B MX346252 B MX 346252B
- Authority
- MX
- Mexico
- Prior art keywords
- procedure
- peptide receptors
- receptors related
- antagonists
- produce antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000014187 peptide receptors Human genes 0.000 title 1
- 108010011903 peptide receptors Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 title 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610746P | 2012-03-14 | 2012-03-14 | |
| US201261644648P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/030696 WO2013138418A2 (en) | 2012-03-14 | 2013-03-13 | Process for making cgrp receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011000A MX2014011000A (es) | 2014-10-13 |
| MX346252B true MX346252B (es) | 2017-03-10 |
Family
ID=49161940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011000A MX346252B (es) | 2012-03-14 | 2013-03-13 | Procedimiento para producir antagonistas de los receptores del peptido relacionado con el gen de calcitonina. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2825044B1 (OSRAM) |
| JP (3) | JP6212534B2 (OSRAM) |
| KR (7) | KR20210022150A (OSRAM) |
| CN (1) | CN104168768B (OSRAM) |
| AU (1) | AU2013232196C1 (OSRAM) |
| BR (1) | BR112014022542A8 (OSRAM) |
| CA (1) | CA2865944C (OSRAM) |
| MX (1) | MX346252B (OSRAM) |
| RU (1) | RU2672056C2 (OSRAM) |
| WO (1) | WO2013138418A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| CN105037210A (zh) * | 2015-05-27 | 2015-11-11 | 江苏大学 | 一种α，β-脱氢-α-氨基酸的合成方法 |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| CN120247907A (zh) * | 2020-05-04 | 2025-07-04 | 大塚制药株式会社 | Iap拮抗剂化合物和中间体及其合成方法 |
| WO2024134683A1 (en) * | 2022-12-21 | 2024-06-27 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of intermediate compounds used in the treatment of migraine |
| CN119431222B (zh) * | 2024-11-04 | 2025-10-17 | 杭州澳赛诺生物科技有限公司 | 一种不对称合成乌布吉泮手性中间体的方法 |
| CN119350337A (zh) * | 2024-12-24 | 2025-01-24 | 药康众拓(北京)医药科技有限公司 | 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途 |
| CN120398716A (zh) * | 2025-04-17 | 2025-08-01 | 珠海奥博凯生物医药技术有限公司 | 一种基于连续流反应技术合成5-氰基-2-氟苯基化合物的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| ATE520661T1 (de) * | 2003-06-27 | 2011-09-15 | Univ Maryland | Heterocyclische verbindungen mit quaternärem stickstoff zum nachweis von wässrigen monosacchariden in physiologischen flüssigkeiten |
| WO2005072308A2 (en) * | 2004-01-29 | 2005-08-11 | Merck & Co., Inc. | Cgrp receptor antagonists |
| US7994325B2 (en) * | 2005-03-14 | 2011-08-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| MX2008014353A (es) * | 2006-05-09 | 2008-11-24 | Merck & Co Inc | Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos. |
| AU2007332898A1 (en) * | 2006-12-08 | 2008-06-19 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
| US8097750B2 (en) * | 2006-12-20 | 2012-01-17 | Brandeis University | Cinchona alkaloid-catalyzed asymmetric mannich reactions |
| EP2146712A4 (en) * | 2007-04-16 | 2010-10-13 | Merck Sharp & Dohme | HETEROCYCLIC ARYL-CGRP RECEPTOR ANTAGONISTS |
| WO2008153849A1 (en) * | 2007-06-05 | 2008-12-18 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| JP5233457B2 (ja) * | 2007-07-17 | 2013-07-10 | セントラル硝子株式会社 | 新規な含フッ素ジカルボン酸およびそれを用いた新規な高分子化合物 |
| KR101098335B1 (ko) * | 2008-07-18 | 2011-12-26 | 성균관대학교산학협력단 | 신코나 기재 이작용성 유기 촉매 및 이를 이용한 메소-고리산무수물의 비대칭 고리 열림 반응을 통한 키랄성헤미에스터의 제조방법 |
| AU2009283085A1 (en) * | 2008-08-20 | 2010-02-25 | Merck Sharp & Dohme Corp. | Non-amidic linkers with branched termini as CGRP receptor antagonists |
| US8623859B2 (en) * | 2008-08-22 | 2014-01-07 | Evotec Ag | Bradykinin B1 antagonists |
| AU2009288206A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide CGRP receptor antagonists |
| JP5449540B2 (ja) * | 2009-06-05 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| WO2011005731A2 (en) * | 2009-07-08 | 2011-01-13 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonist |
| EP2458991A4 (en) * | 2009-07-27 | 2012-12-12 | Merck Sharp & Dohme | RADIOACTIVELY MARKED CGRP ANTAGONISTS |
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US8883807B2 (en) * | 2010-11-12 | 2014-11-11 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane CGRP receptor antagonists |
-
2013
- 2013-03-13 KR KR1020217005005A patent/KR20210022150A/ko not_active Abandoned
- 2013-03-13 JP JP2015500541A patent/JP6212534B2/ja active Active
- 2013-03-13 KR KR1020257005576A patent/KR20250028525A/ko active Pending
- 2013-03-13 MX MX2014011000A patent/MX346252B/es active IP Right Grant
- 2013-03-13 RU RU2014141158A patent/RU2672056C2/ru active
- 2013-03-13 CA CA2865944A patent/CA2865944C/en active Active
- 2013-03-13 AU AU2013232196A patent/AU2013232196C1/en active Active
- 2013-03-13 KR KR1020227041223A patent/KR20220164616A/ko not_active Ceased
- 2013-03-13 KR KR1020217029942A patent/KR20210116717A/ko not_active Abandoned
- 2013-03-13 CN CN201380013890.3A patent/CN104168768B/zh active Active
- 2013-03-13 BR BR112014022542A patent/BR112014022542A8/pt not_active Application Discontinuation
- 2013-03-13 KR KR1020207001976A patent/KR102220242B1/ko active Active
- 2013-03-13 KR KR1020247001330A patent/KR20240010553A/ko not_active Ceased
- 2013-03-13 KR KR1020147025146A patent/KR102071278B1/ko active Active
- 2013-03-13 EP EP13760317.1A patent/EP2825044B1/en active Active
- 2013-03-13 WO PCT/US2013/030696 patent/WO2013138418A2/en not_active Ceased
-
2017
- 2017-09-19 JP JP2017178964A patent/JP6572273B2/ja active Active
-
2019
- 2019-08-13 JP JP2019148465A patent/JP6743256B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018030858A (ja) | 2018-03-01 |
| RU2672056C2 (ru) | 2018-11-09 |
| BR112014022542A8 (pt) | 2023-04-11 |
| CN104168768B (zh) | 2017-03-01 |
| KR20240010553A (ko) | 2024-01-23 |
| KR20250028525A (ko) | 2025-02-28 |
| KR102220242B1 (ko) | 2021-02-25 |
| CA2865944A1 (en) | 2013-09-19 |
| JP6212534B2 (ja) | 2017-10-11 |
| KR20210022150A (ko) | 2021-03-02 |
| AU2013232196B2 (en) | 2016-12-01 |
| MX2014011000A (es) | 2014-10-13 |
| BR112014022542A2 (OSRAM) | 2017-06-20 |
| KR20140138705A (ko) | 2014-12-04 |
| EP2825044B1 (en) | 2018-08-15 |
| KR20210116717A (ko) | 2021-09-27 |
| WO2013138418A2 (en) | 2013-09-19 |
| WO2013138418A3 (en) | 2014-05-30 |
| EP2825044A4 (en) | 2015-12-02 |
| AU2013232196A1 (en) | 2014-08-21 |
| KR20200011559A (ko) | 2020-02-03 |
| JP6743256B2 (ja) | 2020-08-19 |
| RU2014141158A (ru) | 2016-05-10 |
| JP2019206586A (ja) | 2019-12-05 |
| CA2865944C (en) | 2020-12-08 |
| AU2013232196C1 (en) | 2017-03-16 |
| KR102071278B1 (ko) | 2020-03-03 |
| KR20220164616A (ko) | 2022-12-13 |
| CN104168768A (zh) | 2014-11-26 |
| JP6572273B2 (ja) | 2019-09-04 |
| EP2825044A2 (en) | 2015-01-21 |
| JP2015516946A (ja) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346252B (es) | Procedimiento para producir antagonistas de los receptores del peptido relacionado con el gen de calcitonina. | |
| CO2017001152A2 (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock) | |
| EA201591087A1 (ru) | Новые производные бензимидазола в качестве антагонистов рецептора ep4 | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| MX2013005246A (es) | Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano. | |
| CO6410295A2 (es) | Derivados de indol como antagonistas del receptor crth2 | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| UY34387A (es) | Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización. | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| EA201491996A1 (ru) | Антагонисты st2l и способы их применения | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
| EA201692412A1 (ru) | Синтез полициклических карбамоилпиридоновых соединений | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| EA201891376A1 (ru) | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов | |
| UY34660A (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| MX2017012910A (es) | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
| EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
| MX374383B (es) | Derivados de carboxamida como inhibidores de smurf-1 | |
| CU20200038A7 (es) | Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |